Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Agrawal

Showing results (291-300 of 293) with videos related to

Pageof 30
Sort By:
You have reached the last page of results.This site can display upto 293 results.
The EMBO Journal|October 12, 2017
Increased localization of APP-C99 in mitochondria-associated ER membranes causes mitochondrial dysfunction in Alzheimer diseaseMarta Pera, Delfina Larrea, Cristina Guardia-Laguarta, et al.
Biorxiv : the Preprint Server for Biology|December 15, 2025
Upregulation of MAM by C99 disrupts ACSL4 activity and phospholipid homeostasis in Alzheimer's disease modelsJ Montesinos, T D Yun, I D Salomón-Cruz, et al.
British Journal of Cancer|October 11, 2012
Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trialsH M Earl, L Hiller, J A Dunn, et al.
Pageof 30

Showing results (291-300 of 293) with videos related to

Sort By:
Pageof 30
You have reached the last page of results.This site can display upto 293 results.
The EMBO Journal|October 12, 2017
Increased localization of APP-C99 in mitochondria-associated ER membranes causes mitochondrial dysfunction in Alzheimer diseaseMarta Pera, Delfina Larrea, Cristina Guardia-Laguarta, et al.
Biorxiv : the Preprint Server for Biology|December 15, 2025
Upregulation of MAM by C99 disrupts ACSL4 activity and phospholipid homeostasis in Alzheimer's disease modelsJ Montesinos, T D Yun, I D Salomón-Cruz, et al.
British Journal of Cancer|October 11, 2012
Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trialsH M Earl, L Hiller, J A Dunn, et al.
Pageof 30